Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Financing Receivable, Past Due [Line Items]
Revenue	$ 6,942	$ 22,266	$ 17,593	$ 31,143
Interest expense	80	94	160	239
Manufacturing, research and development	1,480	1,542	3,381	3,090
Depreciation and amortization expense	626	811	1,330	2,493
General and administrative	3,018	3,360	6,178	6,245
Other income, net	(991)	892	(1,712)	2,107
Income tax expense	182	3,528	1,269	4,467
Net income (loss)	565	13,970	4,043	17,359
Change in fair value of acquisition-related contingent consideration		(147)		(147)
Other revenue			480	496
Financing Receivable [Member]
Financing Receivable, Past Due [Line Items]
Revenue	6,828	11,805	17,243	20,484
Interest expense	80	94	160	239
Manufacturing, research and development
Depreciation and amortization expense
General and administrative	2	950	104	1,134
Other income, net	(991)	892	(1,712)	2,107
Income tax expense
Net income (loss)	5,755	11,653	15,267	21,218
Change in fair value of acquisition-related contingent consideration
Other revenue
Pharmaceutical Development Services [Member]
Financing Receivable, Past Due [Line Items]
Revenue	114	10,461	350	10,659
Interest expense
Manufacturing, research and development	1,480	1,542	3,381	3,090
Depreciation and amortization expense	625	809	1,329	2,490
General and administrative	905	983	1,940	2,088
Other income, net
Income tax expense
Net income (loss)	(2,896)	7,274	(5,820)	3,634
Change in fair value of acquisition-related contingent consideration		(147)		(147)
Other revenue			480	496
Holding Company And Other [Member]
Financing Receivable, Past Due [Line Items]
Revenue
Interest expense
Manufacturing, research and development
Depreciation and amortization expense	1	2	1	3
General and administrative	2,111	1,427	4,134	3,023
Other income, net
Income tax expense	182	3,528	1,269	4,467
Net income (loss)	$ (2,294)	(4,957)	(5,404)	(7,493)
Change in fair value of acquisition-related contingent consideration
Other revenue